Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)".
作者信息
Rui Xin, Gu Tingting, Zhou Jiaquan
机构信息
Department Of Urology, Ningbo No.2 Hospital, Ningbo, Zhejiang, China.
Department of Urology, Hainan Affiliated Hospital of Hainan Medical University(Hainan General Hospital), Haikou, Hainan, China
出版信息
J Immunother Cancer. 2025 Apr 1;13(4):e012084. doi: 10.1136/jitc-2025-012084.
Abstract
摘要
相似文献
1
Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)".关于“纳武利尤单抗用于局部肌层浸润性尿路上皮癌放化疗的辅助治疗：一项多中心、单臂、II期研究者发起试验（NEXT）的初步分析”的评论
J Immunother Cancer. 2025 Apr 1;13(4):e012084. doi: 10.1136/jitc-2025-012084.
2
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT).纳武单抗用于局部肌肉浸润性尿路上皮癌放化疗辅助治疗：一项多中心、单臂、II期研究者发起试验（NEXT）的初步分析
J Immunother Cancer. 2025 Mar 18;13(3):e010572. doi: 10.1136/jitc-2024-010572.
3
Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT).根治性膀胱切除术联合免疫治疗局部晚期膀胱癌的放射治疗 - 一项前瞻性、单臂、多中心 II 期试验（RACE IT）的研究方案。
BMC Cancer. 2020 Jan 3;20(1):8. doi: 10.1186/s12885-019-6503-6.
4
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.纳武利尤单抗辅助治疗与安慰剂用于肌肉浸润性尿路上皮癌。
N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442.
5
Real-world evaluation of nivolumab utilization in adjuvant treatment of localized muscle-invasive urothelial carcinoma.真实世界中纳武利尤单抗在局限性肌层浸润性尿路上皮癌辅助治疗中的应用评价。
Fr J Urol. 2024 Dec;34(13):102744. doi: 10.1016/j.fjurol.2024.102744. Epub 2024 Sep 17.
6
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.高风险肌肉浸润性尿路上皮癌根治术后辅助纳武利尤单抗的健康相关生活质量：来自 3 期 CheckMate 274 试验的结果。
Eur Urol Oncol. 2022 Oct;5(5):553-563. doi: 10.1016/j.euo.2022.02.003. Epub 2022 Mar 11.
7
Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.伊匹单抗和纳武单抗诱导治疗后行巩固性放化疗作为尿路上皮膀胱癌的器官保留治疗：INDIBLADE试验的研究方案
Front Oncol. 2023 Aug 29;13:1246603. doi: 10.3389/fonc.2023.1246603. eCollection 2023.
8
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.纳武单抗治疗肌肉浸润性尿路上皮癌（CheckMate 274研究）：通俗易懂的总结
Future Oncol. 2023 Feb;19(6):413-426. doi: 10.2217/fon-2022-1294. Epub 2023 Mar 15.
9
Clinical Efficacy and Safety of Nivolumab in Malignant Non-Pleural Mesothelioma: A Multicenter, Open-Label, Single-Arm, Japanese Phase II Trial (Viola) Protocol.纳武利尤单抗治疗恶性非胸膜间皮瘤的临床疗效与安全性：一项多中心、开放标签、单臂、日本II期试验（Viola）方案
Oncology. 2023;101(4):257-261. doi: 10.1159/000528791. Epub 2022 Dec 23.
10
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.辅助纳武利尤单抗对比根治性手术后高风险肌层浸润性尿路上皮癌患者的安慰剂：III 期 CheckMate 274 试验中入组的日本患者的亚组分析。
Jpn J Clin Oncol. 2023 Jan 6;53(1):16-25. doi: 10.1093/jjco/hyac155.
引用本文的文献
1
Response to: Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)".对《关于纳武利尤单抗用于局部肌层浸润性尿路上皮癌放化疗辅助治疗：一项多中心、单臂、II期研究者发起试验（NEXT）的初步分析》评论的回应
J Immunother Cancer. 2025 May 26;13(5):e012378. doi: 10.1136/jitc-2025-012378.
本文引用的文献
1
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT).纳武单抗用于局部肌肉浸润性尿路上皮癌放化疗辅助治疗：一项多中心、单臂、II期研究者发起试验（NEXT）的初步分析
J Immunother Cancer. 2025 Mar 18;13(3):e010572. doi: 10.1136/jitc-2024-010572.
2
A perspective review on the systematic implementation of ctDNA in phase I clinical trial drug development.关于循环肿瘤DNA（ctDNA）在I期临床试验药物研发中的系统应用的前瞻性综述。
J Exp Clin Cancer Res. 2025 Mar 1;44(1):79. doi: 10.1186/s13046-025-03328-4.
3
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.根治性膀胱切除术与三联疗法治疗肌层浸润性膀胱癌：多机构倾向评分匹配和加权分析。
Lancet Oncol. 2023 Jun;24(6):669-681. doi: 10.1016/S1470-2045(23)00170-5. Epub 2023 May 12.
4
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.纳武利尤单抗辅助治疗与安慰剂用于肌肉浸润性尿路上皮癌。
N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442.
5
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).国家癌症研究所患者报告结局版通用不良事件术语标准（PRO-CTCAE）的制定。
J Natl Cancer Inst. 2014 Sep 29;106(9). doi: 10.1093/jnci/dju244. Print 2014 Sep.
6
Prostate-cancer mortality at 11 years of follow-up.前列腺癌死亡率随访 11 年后。
N Engl J Med. 2012 Mar 15;366(11):981-90. doi: 10.1056/NEJMoa1113135.
Zotero 插件